You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023326023
Dec 2023103010
Jan 20246406
Feb 20245804
Mar 20244000
Apr 20245402
May 20244602
Jun 20246304
Jul 20245403
Aug 20244603
Sep 20244201
Oct 20244407
Nov 20245403
Dec 20248003
Jan 20254203
Feb 2025103
Mar 2025001
Apr 2025001
May 2025006
Jun 2025003
Total1117088